First drug approved for rare condition that inflames blood vessels

(HealthDay)—Nucala (mepolizumab) has been approved by the U.S. Food and Drug Administration as the first remedy to treat adults with eosinophilic granulomatosis with polyangiitis, a rare autoimmune disease that leads to inflammation of the blood vessels.

Other symptoms of the condition, formerly called Churg-Stress syndrome, include asthma and an overabundance of an infection-fighting white blood cell called an eosinophil. The inflamed may affect the lungs, intestines, skin, heart and nervous system.

The condition affects a total of about 11 out of every one million people in United States, the FDA said Tuesday in a news release.

"Patients taking Nucala in clinical trials reported a significant improvement in their symptoms," said Dr. Badrul Chowdhury, director of the FDA's Division of Pulmonary, Allergy and Rheumatology Products.

Nucala, a once-monthly injection, was first approved in 2015 to treat people 12 and older with a certain type of , the FDA said. The drug's most common side effects include headache, injection-site reaction, back pain and fatigue.

People who are prone to a "hypersensitive" allergic reaction shouldn't take the drug, and those who are taking an inhaled corticosteroid medication to treat asthma should not abruptly stop the remedy, the agency warned.

Nucala is produced by the British pharma firm GlaxoSmithKline, whose U.S. headquarters are in Warren, N.J.


Explore further

FDA approves admelog for diabetes

More information: SOURCE: Dec. 12, 2017 press release, U.S. Food and Drug Administration


Visit the FDA to learn more.

Copyright © 2017 HealthDay. All rights reserved.

Citation: First drug approved for rare condition that inflames blood vessels (2017, December 12) retrieved 15 September 2019 from https://medicalxpress.com/news/2017-12-drug-rare-condition-inflames-blood.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
14 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more